About the Event
AOBiome Therapeutics has developed a natural topical biologic spray that in a Phase 2B trial proved to be an effective treatment atopic dermatitis, an inflammatory skin condition with a market value of nearly $4B in the U.S. alone.
It is as a safe as a water, making it an excellent choice for a first line therapy for mild to moderate itch and inflammation from dermatitis, acne, rosacea, and psoriasis.
Join our webinar with AOBiome President & CEO, Todd Krueger, as he discusses the company’s science, their upcoming Phase 3 clinical trial, and the path to commercialization.